Why the study?
Does alteplase compared to streptokinase, and heparin compared to no heparin, improve 6-month survival in patients with acute myocardial infarction?
Population
20,891 patients with acute myocardial infarction recruited into the GISSI-2 Study and the International Study
Comparison
Alteplase or streptokinase, with or without… vs Streptokinase and no heparin
Design
RCT, 2x2 factorial study design, open
Follow-up
6 months
Loading...
Alteplase and heparin confer no 6-month survival benefit over streptokinase or none; confirms comparable effectiveness of these regimens in acute MI.
Does alteplase compared to streptokinase, and heparin compared to no heparin, improve 6-month survival in patients with acute myocardial infarction?
In patients with acute myocardial infarction, there is no significant difference in 6-month mortality between alteplase and streptokinase, or between the addition of heparin versus no heparin.
A 1992 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: